Dr. Jason Adam Zell, DO

Dr. Zell practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Zell's NPI, 1568666014, was assigned on June 11, 2007. Dr. Zell graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 2001. Dr. Zell holds California license 20A8352.

Dr. Zell's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Zell's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zell practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zell's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zell is board certified in medical oncology by the American Board of Internal Medicine. Dr. Zell is licensed in California.

Dmand AI lists breast cancer and colorectal cancer among the conditions Dr. Zell treats.

CMS data shows 196 Medicare services from Dr. Zell across 2 procedure codes in 2024, for 72 Medicare patients. Medicare paid $17,105 for them.

CMS counts 72 Medicare patients who saw Dr. Zell in 2024. The largest group is 75 to 84, with 29 patients. 75% of them have cancer, and 75% have high blood pressure. 42% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zell's median patient age at 65, with 52% women.

In 2024, Dr. Zell wrote 115 Medicare Part D claims for 21 patients. 65% of them were for generic drugs. CMS names the drug for 49 of them, across 3 drugs with 11 or more claims each, at $214,085 in total drug cost. In 2023, CMS named 93 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Zell for performance year 2024, reported through an alternative payment model (APM). Dr. Zell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zell as offering telehealth.

Dmand AI links 95 papers to Dr. Zell, published from 2005 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Colorectal Neoplasms, California and Lung Neoplasms. Dr. Zell has published most often in J Thorac Oncol. Dr. Zell's most frequent co-authors are Sai-Hong I I. Ou, MD, Michael J Stamos, MD and Frank L Meyskens.

Dmand AI links Dr. Zell to 5 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Adenomatous Polyps, Rectal Diseases and Adenoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 1 general payment to Dr. Zell from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $88.

Dmand AI lists 4 awards for Dr. Zell, most recently Physician of Excellence in 2023. Dr. Zell serves on The Hope Foundation/Dr. Charles Coltman Fellowship Award Committee and Gastrointestinal Oncology Editorial Board Journal of Adolescent and Young Adult Oncology.

Dr. Zell graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 2001. Dr. Zell is a member of AACR, AOA, ASCO and ASH.

Dr. Zell is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.